Physician profile
Rohit K Patel
NPI 1922260496
$13,410.05
in general payments reported to CMS, 2019-2025
50 companies · $1,896 in 2025
The $1,896 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,855 · 2020: $1,793 · 2021: $1,301 · 2022: $1,640 · 2023: $1,752 · 2024: $2,173 · 2025: $1,896.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,821.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,820.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,162.45 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,499.63 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $1,332.14 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $1,273.52 | 2019-2025 | Krystexxa, Repatha, Otezla |
| Abbvie INC. | $801.70 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $767.19 | 2019-2022 | |
| Amarin Pharma, INC. | $514.93 | 2019-2022 | |
| Pfizer INC. | $457.20 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $407.65 | 2019-2024 | Jardiance, Tradjenta, Synjardy |
| Allergan, INC. | $385.37 | 2019-2020 | |
| Abbott Laboratories | $360.58 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Bayer Healthcare Pharmaceuticals INC. | $270.04 | 2021-2025 | |
| Kowa Pharmaceuticals America, INC. | $261.24 | 2021-2025 | Zoryve, Seglentis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $257.21 | 2020-2024 | Xifaxan, Trulance |
| Shield Therapeutics INC | $246.85 | 2024-2025 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rohit Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.